cancer

Bristol-Myers Squibb
Biotech

Bristol-Myers CMO on cell therapies: ‘This is the best time to be in drug development’

By Adam Feuerstein

ASH 19 - Fluorescent osteoblast cells
Biotech

Constellation’s blood cancer drug shows strong results, but skepticism may not fade

By Adam Feuerstein

Colorful DNA molecule
Biotech

Merck and Sanofi buy smaller cancer drug firms at big premiums, fueling investor excitement

By Matthew Herper

Infusion pump
Pharmalot

More hospital drug spending is going toward cancer immunotherapies

By Ed Silverman

Eli Lilly headquarters
Biotech

Eli Lilly places the team from a startup it bought in January in charge of its cancer research

By Matthew Herper

Charles L. Sawyers
Health

Longtime cancer researcher Charles Sawyers named first STAT Biomedical Innovation Award winner

By Shraddha Chakradhar

CAR-T Therapy in France
First Opinion

Letting academic medical centers make CAR-T drugs would save billions

By David Mitchell, Saad Kenderian, and S. Vincent Rajkumar

Exercise in space
In the Lab

Exercise helps astronauts cope with side effects of spaceflight. Could it help cancer patients too?

By Shraddha Chakradhar

ASH19 Acute Promyelocytic Leukemia
Pharma

After backlash, Teva will resume supplies of a critical children’s cancer medicine

By Ed Silverman

Human Melanoma Cell
Biotech

Immunotherapies targeting melanoma post encouraging results, new data show

By Adam Feuerstein

Play
The Readout LOUD

Listen: An uncertain Alzheimer’s idea, blockbuster fish oil, & a little self-indulgence

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

MORE Red Blood Cells
Biotech

ASH preview: Celgene, Bluebird, and J&J out with early but telling data in blood cancer

By Adam Feuerstein

David Liu- Broad Retreat
In the Lab

You had questions for David Liu about CRISPR, prime editing, and advice to young scientists. He has answers

By Sharon Begley

Pancreatic cancer cells
Biotech

Halozyme’s lead drug fails; company will cut 55% of workforce in bid for profitability

By Matthew Herper

Business

Amgen acquires stake in BeiGene to expand cancer drug business to China

By Adam Feuerstein

Money and medicine
First Opinion

The ‘cancer growing in cancer medicine’: pharma money paid to doctors

By Vinay Prasad

Pharmalot

Pharmalittle: Rise in drug costs for large employers slows; experimental TB vaccine proves effective

By Ed Silverman

Lung Cancer Cells on green background
Biotech

Mirati takes a turn at the podium with a first look at its KRAS-blocking cancer drug

By Adam Feuerstein

AstraZeneca signage
Biotech

AstraZeneca aims to carve into Merck’s immunotherapy dominance

By Matthew Herper

David Hung
Biotech

Former Axovant CEO David Hung is back — leading a cancer biotech with hefty funding

By Kate Sheridan

Adam's Take

Cel-Sci is publicly upbeat about its cancer drug. Privately it’s trying to sell stock

By Adam Feuerstein

Medicine Hunters Part 2
Special Report

The Medicine Hunters, Part II: Toxic weed fuels a cancer-drug gold rush — and a quandary

By Eric Boodman

Colon cancer cells
Biotech

Blood test maker Guardant enters race for liquid biopsy with colon cancer study

By Matthew Herper

Health

FDA wants stronger warning on breast implants about risks

By Associated Press

Pharmalot

Pharmalittle: Biogen Alzheimer’s drug revival sparks skepticism; docs chide blood-thinner recommendations

By Ed Silverman

Medicine Hunters Part 1
Special Report

The Medicine Hunters, Part I: Before signing up for a trial, one patient wants to know if the drug will be affordable

By Eric Boodman

Zantac
Pharmalot

Consumers sue Sanofi and other drug makers over Zantac link to a possible carcinogen

By Ed Silverman

Pharmalot

Pharmalittle: Four drug companies settle Ohio opioid suit; J&J recalls baby powder due to asbestos

By Ed Silverman

Breast Cancer Cell - pink
Biotech

Seattle Genetics to seek approval for new breast cancer pill after positive clinical trial results

By Adam Feuerstein

Your daily dose of news in health and medicine

Privacy Policy